Exodus Point Capital Management, LP Fibrogen Inc Transaction History

Exodus Point Capital Management, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$15.95 - $25.18 $1.48 Million - $2.33 Million	-92,528 Reduced 83.46%	18,331 $342,000
Q4 2022 Feb 13, 2023	BUY	$13.27 - $17.73 $1.47 Million - $1.97 Million	110,859 New	110,859 $1.78 Million
Q2 2022 Aug 19, 2022	SELL	$7.94 - $12.96 $887,183 - $1.45 Million	-111,736 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$12.02 - $16.79 $811,674 - $1.13 Million	67,527 Added 152.74%	111,736 $1.34 Million
Q4 2021 Feb 11, 2022	SELL	$9.93 - $15.39 $122,079 - $189,204	-12,294 Reduced 21.76%	44,209 $623,000
Q3 2021 Nov 15, 2021	BUY	$10.18 - $26.64 $575,200 - $1.51 Million	56,503 New	56,503 $577,000
Q2 2021 Aug 16, 2021	SELL	$18.57 - $35.68 $289,209 - $555,680	-15,574 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$31.0 - $55.72 $482,794 - $867,783	15,574 New	15,574 $541,000
Q4 2020 Feb 16, 2021	SELL	$37.09 - $48.97 $218,052 - $287,894	-5,879 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$40.47 - $45.5 $237,923 - $267,494	5,879 New	5,879 $242,000

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $31.9M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.